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Abstract
Psoriasis is an erythematous, scaly chronic inflammatory dermatosis and occurs due to 
altered epidermal differentiation and hyperproliferation due to faulty signals that speed 
up the growth cycle of skin cells. Psoriasis reduces quality of life, and psoriatic patients 
generally have higher risk for metabolic disease. Psoriasis is associated with many bur-
dening comorbidities, which often share similar pathogenic features and follow a pro-
gressive pattern. Genetic variation in human genome causes specific kind of disease, and 
nowadays, research is focused on metabolic pathways that trigger psoriasis and related 
comorbidities. In addition, genetic variations are also important for psoriasis treatment 
regime and response. The purpose of this section is to shown to genetic epidemiology, 
pharmacogenetics, immune genetics of psoriasis and related comorbidities.
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1. Introduction
Psoriasis was first thought to originate from a biochemical imbalance due to excessive prolif-
eration of keratinocytes; yet recent researches focused on the investigation of the genetic basis 
of this immunological condition.
Psoriasis, a chronic inflammatory disease, is thought to be closely related to metabolic and 
cardiovascular diseases; however, mortality rate of the disease is rare. Genetic and epide-
miologic studies have also pointed out that cardiovascular and metabolic diseases are more 
prevalent in the community than psoriasis cases in psoriasis cases. Thus, determination of 
genetic variation on genome that triggers both psoriasis and related comorbidities is crucial. 
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In addition, personal genomic variations are important for diagnosis and treatment of the 
psoriasis and related comorbidities effectively.
2. Epidemiology of psoriasis
Psoriasis can affect people of all ages, ethnic origins and genders around the world. There 
are very literatures showing the incidence of the disease, since there is no compulsory reten-
tion of psoriasis case recordings and reliable source constraints. On the other hand, preva-
lence varies among different countries in Europe [1]. Although psoriasis may affect 2% of 
the world population, the incidence of disease varies 0.09–11.4% between different coun-
tries and races [1–4]. The reasons for the variability of prevalence are that the epidemiologi-
cal methods and limitations of the studies differ [2]. Psoriasis is not evident among Latin 
American indigenous, people of Samoa and New Zealand, and in contrast, the prevalence 
is increasing up to 12% in Kasachy [5]. The prevalence of psoriasis in Asian countries or 
Asians common countries is 0.4% in China, 0.3–1% in Japan, and 0.8% in India, while the 
prevalence of West African and American black population was reported as 0.3–0.7% and 
0.7%, respectively [6].
The results have shown that there is a very weak correlation between geographical latitude 
and psoriasis [2, 7]. In contrast, psoriasis is more commonly seen in places where the upper 
latitudes of that are colder and Caucasians are more frequent[5, 8–10]. For example, in twin 
studies carried out in Australia, it has a higher prevalence of psoriasis in southern region of 
cold than the northern region where is warmer [8, 9]. When investigating the regional dis-
tribution of psoriasis cases in Norway, the incidence of disease has been found to increase 
inversely proportional to the temperature rise in the country [10].
According to the global disease burden study conducted in 2010 [11], it has been reported that 
the disability‐adjusted life year increases with age, especially the highest burden of disease 
shown between the ages of 50–69 [2, 11]. Psoriasis is associated with many burdening comor-
bidities, which often share similar pathogenic features and follow a progressive pattern, and 
thus, direct and indirect cost of psoriasis has significant effects on both patients and health 
care systems.
3. Psoriasis as a genetic disease
Genetic factors play a role in psoriasis development; yet, the exact mechanism that triggers 
psoriasis is still unknown. Twin studies, familial aggregation studies, linkage studies, and 
population‐based association studies are all important to understand the effect of the genes in 
heritability of the disease. Nowadays, genome‐wide association studies and linkage studies 
are also frequently used to identify disease mechanism and risk‐related genes. Association 
studies on genome‐wide and a meta‐analysis aim to reveal the potential risk genes and loci of 
genome that emerged comorbidities as a result of these diseases such as s psoriasis.
An Interdisciplinary Approach to Psoriasis4
Psoriasis is a complex disease that not simply explained by Mendelian inheritance rules. 
Lomholt’s study that performed (1954) in an island has determined that 91% of psoriatic 
patients have a previous family history [12]. Earlier studies speculated psoriasis as autosomal 
dominant disease, but the truth is so different [13]. This speculation relies on the fact that 
human lymphocyte antigen gene located in a single locus thus its effects as dominant. That is 
why psoriasis is accepted as a dominant disease [13]. Although dominant inheritance firstly 
goes to foreground in studies to investigate the pattern of inheritance of psoriasis, it has been 
focused on the disease transition by heterogeneous or polygenic in broader studies.
The twin studies rely on the fact, if the disease occurs in monozygotic twins because of phe-
notypical differences between monozygotic twins. This means that environmental factors 
affect the disease because they have identical genetic background. In contrast, dizygotic twins 
have genetic background like brothers or sisters, and thus, phenotypical differences occur as 
a result of genetic or environmental factors or both.
The concordance of psoriasis has greater rates in monozygotic twins than dizygotic twins’; 
thus, genetic factors are important for disease development. In contrast, the rate is never 
reaching to 100% in monozygotic twins so environmental influences for disease development. 
Duffy et al. [8] have reported concordance for psoriasis higher in monozygotic twins (35%) 
when compared to dizygotic twins (12%) in Australian population. The data from National 
Twin Registry System of Denmark had been shown that the concordance of psoriasis in dizy-
gotic twins was 15–30%; yet, the rates rises up to 65–72% in monozygotic twins [14]. The 
Danish Twin Registry System records have shown that monozygotic twins increased risk of 
psoriasis than in dizygotic twins [15]. A twin study has been shown that psoriasis risk has 
been rise up to 3 times in monozygotic twins when compared to fraternal twins [16]. Although 
twin studies have shown strongest genetic background of psoriasis, heritability rate of psoria-
sis never reaches to 100% among monozygotic twins. This missing heritability means environ-
mental factors [15, 16] and epigenetic alterations [17] have effects on psoriasis development.
Psoriasis was diagnosed 6% in first‐degree relatives of patients with psoriasis [18, 19] gen-
erations, settlement in geographical regions and ethnic group studies related to population 
showed that psoriasis is a complex genetic‐based, multifactorial disease [6]. All these data 
showed why psoriasis was accepted as a heritable disease but not 100% as a genetic dis-
ease. Psoriasis was first associated with the major histocompatibility complex (MHC) region 
in the short arm of the 6th chromosome in 1972 [20–22]. MHC is an intense region of the 
genome and contains HLA‐I and HLA‐class human leukocyte antigens. In fact, the 80–200 kb 
long region in the HLA‐C gene region has been accepted as the Psoriasis susceptibility gene 
region (PSOR1) [23]. HLA‐Cw6 in PSOR1 region was associated with psoriasis in many ethnic 
groups and geographical regions [24–27]. However, the risk zones related to subclinical forms 
of the disease vary in patients with psoriasis. For example, HLA‐Cw6 positivity is associated 
with early onset and familial transition of psoriasis [28]. HLA‐CW6 gene region affects the 
response of ustekinumab using in the treatment of psoriasis [29]. Other gene regions (PSORS2 
(17q25), PSORS3 (4q34), PSORS4 (1q), PSORS5 (3q21, PSORS6 (19p13), PSORS7 (1p) PSORS8 
(16q12‐13), PSORS11 (5q31.1‐q33.1), PSORS12 (20q13), and PSORS13 (6q21)) related to psoria-
sis distribute to different chromosomes [13, 30–37].
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4. Immunogenetics of psoriasis
Psoriasis is an immune‐mediated disease and, for that reason, immune‐mediated mechanism 
has been extensively studied. Genetic studies focus on identification reasons that trigger uncon-
trolled proliferation of keratinocytes and recruitment of T cells into the skin. In healthy individ-
uals, T cells are originated from embryonal pluripotent cells by cytokine induction. Immature 
thymocytes are transferred to thymus for proliferation through clonal expansion. T cells are 
specified to helper T cells or cytoxic T cells by adding specific surface antigens (CD4+ or CD8+) 
and differentiating to give response for antigenic signals. In psoriatic skin samples, Th1 cell 
differentiation is up‐regulated and that cause impaired Th1/Th2 balanced [38, 39]. Evidence 
indicates that Th1‐delivered cytokines IL‐1, IL‐2, IL‐6, IL‐8, tumor necrosis factor‐α (TNF‐ α), 
transforming growth factor (TGF) and Granulocyte‐macrophage colony‐stimulating factor are 
upregulated, while Th2‐delivered cytokines IL‐4, IL‐5, and IL‐10 are downregulated [40–44]. 
The cytokines IL‐12 is critical for both T‐cell activation and differentiation also contributes to 
DC/T cell interactions [45]. TNIP1, NFKBIA, IL12B and LCE3D–LCE3E are known suscepti-
bility loci for psoriasis [46], and the variation of IL‐12 is associated with psoriasis in different 
populations [47–49]. Meta analyses have shown that IL‐12B variation (rs3212227, rs6887695) 
has been associated both psoriasis and psoriatic arthritis [50]. IL‐12 and IL‐23 are heterody-
namic cytokines; both of them share same p40 subunit. IL‐12 consists of p35 and p40 subunit 
and IL‐23 consist of p19 and p40 subunits. The metabolic model for psoriasis suggests that 
dermal dendritic cells are secreted IL‐23 by that way trigger Th17 cell line activation. IL‐23 is 
crucial for naive T cell differentiation to Th17. Activated Th17 cells are secreted IL‐17A, IL‐17F, 
IL‐22 and IL‐26 and that proinflammatory cytokines effects epidermal and dermal cells gene 
expression and keratinocyte maturation. For that reason, IL12/IL 23 pathway seems important 
for psoriasis treatment and different studies are performed in that metabolic pathway [51–54].
5. Immunohistochemical parameters
The demonstration of specific markers by immunohistochemical methods in histopathologi-
cal tissue specimens diagnosed as psoriasis is important in terms of supporting and confirm-
ing the diagnosis. We have evaluated most of the cytokines referred to in the pathophysiology 
in immunogenetic section which can be used for immunohistochemical methods. In psoriatic 
tissue, sample Th1‐mediated cytokines IL‐1, IL‐2, IL‐6, IL‐8, tumor necrosis factor‐α (TNF‐α), 
transforming growth factor (TGF) and granulocyte‐macrophage colony‐stimulating factor 
increase and Th2‐mediated cytokines IL‐4, IL‐5, and IL‐10 decrease [40–44].
IL‐17 plays an important role in psoriasis, and recently, both IL‐17 inhibitors and IL‐17receptor 
type A blockers are new monoclonal antibodies which are approved by US FDA [55]. Lee and 
colleagues have immunohistochemically evaluated IL‐17A expressions in different types of 
psoriasis, and the results have shown that samples from palmoplantar and pustular type 
psoriasis samples were stained with IL‐17A strongly, while plaque type samples were stained 
with IL‐17A intermittently [56].
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Macrophage migration inhibitory factor (MIF) is directly related to the severity of clinical 
symptoms, and serum MIF levels are usually high in patients with psoriasis [57]. In contrast, 
immunohistochemical staining by anti‐MIF antibody in psoriatic lesions showed that MIF 
levels are very low [58]. Toll‐like receptors (TLRs) are a group of molecules that play a crucial 
role in innate immunity and also regulate antimicrobial defense. TLR2 is immunohistochemi-
cally staining uniformly in all the layers of the normal deep epidermis that does not lose its 
nuclei, yet TLR2 staining differs in psoriatic skin samples [59, 60]. Panzer and colleagues have 
shown that TLR2 staining is lower in granular and upper spinous, whereas it was strongly 
observed in the lower spinous and basal strata [59]. TLR4 is normally found in all the nuclear 
layers, while it is more pronounced in the upper layers of the basal layer. In psoriatic skin 
lesions, TLR4 was stained weak in the basal layer, yet TLR4 was stained strongly in the upper 
spinous and granular layers [59]. IL‐8 is produced in psoriatic lesions and immunohistochem-
ical demonstration supports disease diagnosis [61]. In a study, evaluating the relationship 
between geographic tongue (GT) and psoriasis has been shown that anti‐CD4, CD8, CD20, 
CD68, S100, and Ki‐67 antibodies results were similar in tissue samples from both diseases, 
and according to that result, geographic tongue is speculates as an oral psoriasis lesion [62].
6. Pharmacokinetics of psoriasis in genetic aspect
Psoriasis is a chronic, non‐curative disease, and thus, effective psoriasis treatment is important 
for long‐term cure and inhibition of disease manifestation. Psoriasis can be treated by topical, 
photo(chemo)therapy, classic systemic drug(methotrexate, cyclosporine, acitretin) and biologic 
agents (infliximab, adalimumab, etanercept). The psoriasis treatment is affected by psoriasis 
type, severity, presence of comorbidities, previous response to other treatments and patients.
Ustekinumab is an anti‐p40 monoclonal antibody which is effective for psoriasis treatment 
via its inhibitor effect of interleukin‐12/23 pathway. By that way, ustekinumab inhibits T 
helper (Th)1 and Th17 pathway and inhibits immune cell activation. In addition, HLA‐Cw+ 
patients have better clinical response to ustekinumab than HLACw‐ ones [29]. Talamonti et al. 
state that HLACw+ patients response to ustekinumab is 9.8 times more efficient than mutant 
genotype. In contrast, TNFAIP3 polymorphism and LCE3B/3C gene deletions have no effect 
on ustekinumab response [29].
TNF‐inhibitors infliximab and adalimumab and the fusion protein, etanercept are used widely 
for psoriasis treatment. Nishikawa and colleagues [63] have shown that JAG2, ADRA2A and 
TLR10 polymorphisms are associated with TNFα response. Prieto‐Pérez and colleagues [64] 
have shown that PGLYR4, ZNF816A, CTNNA2, IL12B, MAP3K1, and HLA‐C genes are asso-
ciated with anti‐TNF response at 3 months, while FCGR2A, HTR2A, and CDKAL1 are related 
anti‐TNF response at 6 months. TNF gene polymorphism is also associated with psoriasis and 
psoriatic arthritis due to its effects on TNF production. Murdaca and colleagues have dem-
onstrated TNF‐α polymorphism on +489 position of the gene effects efficiency of etanercept 
treatment on psoriatic arthritis patients (PsA) [65]. In fact, the idea simply relies on the fact 
that gene polymorphism affects the biological properties of encoded proteins. TNF blockers 
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are widely used for regulation of inflammatory cascade and by that way treatment of the 
immune‐related disease. If polymorphic product of the gene is your pharmaceutical target 
and has different molecular structure, then wild type its means pharmacodynamics of the 
drug varies due to personal variation.
Both IL‐17 antagonists and IL‐17 receptor blockers are accepted as effective and safe for psori-
asis treatment [66]. Brodalumab is a human monoclonal antibody that binds to interleukin‐17 
receptor and waits for US‐FDA approval for psoriasis treatment [55, 67]. IL‐17 expression 
is upregulated in psoriatic skin samples. Both secukinumab and ixekizumab are the cyto-
kine antagonists used for psoriasis treatment [68]. Nowadays, recent studies are focused 
on the relationship between IL‐17 family cytokines (IL‐17A, IL‐17B, IL‐17C, IL‐17D, IL‐17E, 
and IL‐17F) and IL‐17 receptor polymorphisms with psoriasis susceptibility and treatment 
response [69–71].
7. The link between psoriasis and comorbidities in view of genetics
Nowadays, psoriasis is accepted as a systemic disease because of higher rates of obesity, 
depression, psychiatric disorders, diabetes, hyperlipidemia, cardiovascular diseases, arthritis, 
uveitis, ulcerative colitis, Crohn’s disease, and metabolic syndrome among psoriatic patients. 
Even if, the mortality rate of the psoriasis is low, psoriatic patients over 65 have at least two 
comorbidities [72]. Thus, interdisciplinary approach should be an integral part of the routine, 
and also the dermatologist should be careful with psoriasis and related disorders. Although 
the systemic inflammation process during psoriasis development is still unclear, the chronic 
inflammatory process may trigger development of many burden comorbidities in psoriatic 
patients. Many epidemiological studies revealed relationship between psoriasis and diabe-
tes [72, 73]. Aside, the studies have shown that cardiovascular risk increases among patient 
with psoriasis and psoriatic arthritis [74]. In that point, dermatologist should be careful about 
systemic drug usage for psoriasis treatment because medications can sometime trigger main-
tenance factor in the pathogenesis of psoriasis [75–78].
In that section, we would like to evaluate the common mechanism between psoriasis and pso-
riatic comorbidities in molecular and genetic basis. For example, psoriatic patients are more 
prone to develop Crohn’s disease more than general population [79]. The molecular basis of 
Crohn’s disease is activation of CD4+ T cells by intestinal epithelial cells (IECs) and lamina 
propria immune cells and that activate both Th1 and Th17cells and cause elevated level of 
TNFα and Th17‐related cytokine. Th1 and Th17 differentiation is common both in psoriasis 
and Crohn’s disease; for that reason, TNF inhibitors are effective for treatment of Crohn’s 
disease as psoriasis [80].
7.1. Psoriatic arthritis
Joint involvements in patients with psoriasis were put forward for the first time by Alibert 
in 1818 [81, 82]. Psoriatic arthritis is a negative spondyloarthropathy [71–83]. Important 
radiological findings of the psoriatic arthritis are peripheral joint involvement, destructive 
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and proliferative changes, spinal involvement, interphalangeal joint ledge, fibroosteitis and 
acroostelolysis [84, 85]. Strong genetic relationship is remarkable between positive family his-
tory [81, 86] and human leukocyte antigen (HLA) class II alleles for psoriatic arthritis [87–89].
Psoriatic arthritis (PsA) is diagnosed in 25–34% of psoriatic patients [90]. Psoriasis with-
out joint involvement (PsO) and psoriatic arthritis (PsA) occur as a result of autoimmune 
responses that are triggered by genetic and environmental factors. The pathogenesis of pso-
riasis only (PsO) and psoriatic arthritis (PsA) may be explained impaired cytokine levels [91].
To clarify immungenetics mechanism of psoriatic arthritis has been focused on human leuko-
cyte antigen (HLA). HLA gene region is located on the short arm of chromosome 6. This region 
is highly polymorphic depending on mutation and recombination [92]. Psoriatic arthritis associ-
ates with various HLA risk haplotype such as HLA‐B7 B57 B13, B16, B17, DR7, B38, B39, CW6, 
and B27 [89, 93, 94]. While CW6 HLA‐alleles were associated with early onset of the disease [95], 
HLA‐B38 and HLA‐B39 were associated with polyarthritis [87], and HLA‐B27 was associated 
with dorsal involvement. Positivity of human leukocyte antigen “HLA‐B27” in psoriatic arthri-
tis patients makes a higher risk of arthritis compared to other HLA alleles [90, 96]. In Turkish 
population, we have found that HLA‐B27 positivity increased the risk of psoriasis and psoriatic 
arthritis 5 to 10 times more, respectively [97]. There are various molecular‐based hypotheses 
such as molecular mimicry, defective immunity, heavy chain folding incorrectly, and deteriora-
tion of HLA‐B27 allele for relationship between HLA‐B27 and psoriatic arthritis (PsA) [97].
7.2. Obesity
Storing energy in the form of triacylglycerols is considered to be the primary task of adi-
pocytes; but adipocytes have physically some additional functions such as preservation of 
internal organs, regulating temperature, storage of lipid‐soluble vitamins, steroid metabo-
lism, immunity, and being assigned in inflammatory processes [98, 99]. Adipose tissue runs 
like as an endocrine tissue as the sympathetic system regulators with hormone and cytokine 
production during the regulation of energy metabolism [100]. Adipose tissue plays also an 
important role in homeostasis besides production, secretion such as TNF‐alpha, IL‐8, mono-
cyte chemoattractant protein 1, cytokines and chemokines and storing energy in the form of 
fatty acids, together with the adipokines, leptin, adiponectin, resistin, such as pro‐inflamma-
tory and anti–inflammatory factors [98, 101].
The risk of diseases such as a high rate of insulin resistance, type 2 diabetes, dyslipidemia, gout, 
hypertension, and cardiovascular involvement is higher in obese individuals [102–107, 110]. 
Adipokine tissue secretes cytokines thus increasing volume or amount of adipokine tissue cause 
increasing the amount of circulating cytokines. Then, elevated amount of cytokines causes arte-
riosclerosis and insulin resistance and to induce hypertension and type 2 diabetes [108].
In a study that investigated the risk of obesity in patients with psoriasis, same sex siblings and 88 
psoriasis outpatients were compared by calculating the BMI. The result of this study has obtained 
a significant relationship between the severity of psoriasis and BMI [109]. Duarte et al. have found 
that it was a statistically significant relationship between obesity and psoriasis severity on patients 
with psoriasis by using different parameters, such as BMI and waist/hip ratio [110]. It was shown 
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to be positive commensurate with psoriasis risk of weight gain and high BMI in another study 
performed in the United States with 809 psoriasis patients followed for 12 years [111]. Obesity 
was determined to be more than psoriasis only (PSO) patients [112–114], and it was determined 
that obesity increases the risk of psoriatic arthritis in individuals under 18 years of age [115].
7.3. The impaired glucose tolerance and diabetes
Glucose intolerance, diabetes, and obesity are more frequent in patients with psoriasis [74, 75, 116–
119]. The study conducted by Onsun et al. has found that diabetes was significantly more frequent 
in patients with psoriasis when compared to the incidence of psoriasis in patients with diabetes 
[120]. Azfar and his colleagues have found that patients with severe psoriasis involvement have 
more risk of with diabetes; in contrast, they concluded that psoriasis was an independent risk fac-
tor for type 2 diabetes [121]. Armesto and colleagues have found that occurrence of risk of type 2 
diabetes was found to have higher, late‐onset, nonfamilial transmission, but in patients with joint 
involvement [122]. Finley et al. have shown that expression of IL‐17 and IL‐20 is elevated in dia-
betic wounds, and they emphasized the psoriasis and diabetes link via cytokines [123]. Granata 
et al. have demonstrated that IL‐23/IL‐17, and IL‐18 are main cytokines that has central role for 
obesity, type 1 diabetes, and psoriasis [124]. Eirís et al. have demonstrated that IL12B rs6887695 
and rs3212227 increase the type 2 diabetes risk approximately 3 and 6 times, respectively [125]. 
In addition, IL23 receptor polymorphism was also found significantly associated with diabetes in 
psoriatic patients [125]. Presta et al. have found that polymorphism in the 3′untranslated region of 
IL‐18 gene increases the insulin sensitivity risk [126]. In addition to literature, we have evaluated 
the diabetes risk among psoriasis patients; yet, we could not find any significant relation between 
TNF‐α‐238 G/A and TNF‐α‐308 G/A polymorphisms with diabetes [127].
7.4. Cardiovascular diseases
The epidemiological studies have shown that cardiovascular morbidity and mortality 
increased in patients with psoriasis in Refs. [77, 78, 128, 129]. Inflammation located in patho-
genesis of psoriasis is known to cause metabolic and cardiovascular disease. The molecular 
relationship between psoriasis and cardiovascular disease may be explained by T cell acti-
vation and enhance of Th1 cytokine production (TNF‐α, IL‐1β, IL‐10, and IFN). The TNF‐α 
and IL‐1 trigger oxidative stress causes migration of leukocytes into atherosclerotic plaques 
[101], so TNF inhibitors have beneficial effects on prevention of cardiovascular events both in 
psoriasis and psoriatic arthritis [130]. Our study group has evaluated hypertension risk and 
psoriasis. eNOS Glu298Asp single‐nucleotide polymorphism has found to be increased in 
hypertensive psoriatic patients when compared with healthy volunteers [131]. In contrast, we 
could not find relationship between TNF‐α‐298 and TNF‐α‐308 polymorphisms with hyper-
tension and cardiovascular disease [127].
7.5. Metabolic syndrome
Metabolic syndrome is associated with conditions such as physical inactivity and improper 
diet, occurring nutrition changes, and daily lifestyle. It is characterized as a disease of civiliza-
tion by high mortality and morbidity [132].
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It is a fact that metabolic syndrome and its components are often seen in patients with psoria-
sis. Also, polymorphism may be triggering both psoriasis and metabolic syndrome together. 
Abdel Hay and Rashed have shown that leptin gene 2548G/A polymorphism increases risk of 
both psoriasis and metabolic syndrome [133].
7.6. Psychological trauma and addiction
Psoriasis is a chronic skin disease that negatively affects the quality of life in many ways. 
Patients with psoriasis reduce quality of life with comorbidities like arthritis. Psoriasis can 
lead not only to physical health problems, but also to mental and social health problems. 
Psoriatic lesions that occur especially in hands, face, and on the scalp cause shame, embarrass-
ment, and social inhibition in social life and by that way increase the risk of depression, anxi-
ety, lack of self‐confidence, smoking and alcohol addiction, and trend of suicidal thoughts in 
patients with psoriasis [134].
Kurd et al. have shown that depression, anxiety, and suicidality risk increases 1.39, 1.31, and 1.44 
times more in psoriatic patients than healthy people, respectively [135]. Psoriatic patients are 
more prone to psychiatric comorbidities and suicidal ideation than other dermatological diseases 
[136]. Deveci and et al. have found significantly higher depression rate and suicide attempts in 
cases with psoriasis when compared to patients with other dermatological problems [137].
Use of alcohol and tobacco makes difficult the therapeutic harmony and also increases the tox-
icity of the drug besides reducing the effectiveness of systemic anti‐psoriatic drug. Excessive 
alcohol intake can induce production of proinflammatory cytokine in various cell types and 
increase the cell lymphocyte proliferation and activation [138]. Serotonin may be triggered 
psoriasis as a growth factor that promotes keratinocyte proliferation [139]. The serotonin 
transporter gene promoter region and serotonin2A receptor gene have been found associated 
with psoriasis in Thai population [140, 141].
8. Conclusions
What would cause the metabolic alteration among psoriatic patients? Does systemic drug 
usage in long term causes comorbidities in patients with psoriasis? or Is it the domino effect 
of impaired metabolism? It has not reached a consensus about it.
Advances in understanding the immune‐mediated pathological mechanisms of psoriasis 
will be highlighted with the relationship between psoriasis and psoriasis‐related comorbidi-
ties. Much psoriatic comorbidity may be triggered by the cytokines and chemokines, which 
were secreted by T‐cells, keratinocytes, and antigens presenting cells after keratinocyte hyper 
proliferation. Hence, molecular approaches are important to identify the link immunogenic 
mechanism with psoriasis‐related comorbidities in view of molecular pathways.
Determinations of genomic risk profile of the psoriatic patients allow diagnosing of psoriasis 
and its related comorbidities at an early stage; hence, the life quality can be increased by treating 
them earlier. In addition, evidence‐based information helps physicians to make clear decision 
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and help to minimize medical errors as well as unnecessary drug usage. As a sum, this informa-
tion allows to increase treatment cost and work loss. In addition, pharmacogenomics of drugs 
among psoriatic patients is tightly related to personal variations on genome, and thus, complex 
genetic heterogeneity affects the treatment power.
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